International Pharmaceutical Aerosol Consortium

Tweet this page
<
2020
2021
2022
2023
2024
>
Registration as it was on 04 Mar 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

200,000€ - 299,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

0.5 Fte (2)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    International Pharmaceutical Aerosol Consortium   (IPAC)

    EU Transparency Register

    602537137644-70 First registered on 16 Mar 2020

    Goals / Remit

    The International Pharmaceutical Aerosol Consortium (IPAC) was formed in 1989 in response to the mandates of the Montreal Protocol on Substances that Deplete the Ozone Layer and fully supported a timely and effective transition away from chlorofluorocarbons (CFCs) used in pressurised metered dose inhalers (pMDIs) under the Montreal Protocol that balanced patient health and environmental concerns. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC members research and develop CFC-free products – HFC pMDIs, dry powder inhalers (DPIs) and soft mist inhalers (SMIs). In light of this history and deep expertise, IPAC is uniquely positioned to serve as a resource in efforts related to the intersection of environmental policies and inhaled therapies. IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon & Teva.

    Main EU files targeted

    IPAC's focus is on environmental/climate change policies related to fluorinated gases and, in particular, hydrofluorocarbons (HFCs) 134a and 227ea which are used as aerosol propellants in inhaled therapies. IPAC is engaging with the Commission and other stakeholders on the review of the European F-Gases Regulation: Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases.

    Address

    Head Office
    1500 K Street, NW Suite 1100
    Washington 20005
    UNITED STATES
    EU Office
    1500 K Street, NW Suite 1100
    Washington 20005
    UNITED STATES

    Website

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    25%2

    Lobbyists (Full time equivalent)

    0.5

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Trade and business associations

  • Networking

    Affiliation

    IPAC is an associate member of the Alliance for Responsible Atmospheric Policy, please see: http://alliancepolicy.org/.

    Member organisations

    IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon, and Teva. See www.ipacinhaler.org.

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    200,000€ - 299,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    Name
    fti consulting

    Closed year Costs

    200,000€ - 299,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    Consultation Forum according to Art. 23 of Regulation (EU) No 517/2014 on fluorinated greenhouse gases#X03338#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3338 #Member #C#Industry, Civil society

    Groups (European Parliament)

    Climate change, biodiversity and sustainable development

    Communication activities

    IPAC's activities in 2023 are summarized below.
    IPAC has engaged with the European Commission, staff/members of Parliament, and Council on issues relevant to the use of HFCs as medical propellants. We submitted a joint stakeholder letter to many senior EU policymakers in January 2023. A copy of the letter is posted on IPAC's website: www.ipacinhaler.org.

    IPAC also responded to a public questionnaire on ECHA Reach/PFAS issues in May and September. A copy is available on www.ipacinhaler.org.

    Other activities

    None declared

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 09 Nov 2021 Location video conference
      Subject Fluorinated Gases regulation
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Caroline Boeshertz (Cabinet member)
Download this datacard